Cardiovascular disease
Conditions
Interventions
Modern drug plaque regression treatment group:PCSK9
Traditional lipid-lowering drug treatment group:Traditional lipid-lowering drug
Sponsors
Shanghai Tongji Hospital, Tongji University School of Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing coronary angiography with clinically confirmed or suspected coronary heart disease; 2. Visual diameter stenosis was about 70+/-10%; 3. The measured value of baseline FFR 0.7-0.8; 4. Agree to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Left main stenosis > 50%; 2. The "criminal" lesion of ACS patients; 3. Patients with cardiac insufficiency (NYHA grade 3 or above); 4. Severe arrhythmia;Severe calcification; 5. Non-in-situ lesions; 6. After CABG surgery; 7. FFR and intravascular image data cannot be obtained.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Major adverse cardiac events (MACE) in 2 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac death;Ischemia-driven emergency revascularization;Target vessel-related myocardial infarction;FFR value change and PAV change at 1 year; | — |
Countries
China
Contacts
Public ContactXuebo Liu
Shanghai Tongji Hospital, Tongji University School of Medicine
Outcome results
None listed